All In Biotech

Drug Trial Radar · NCT07699939

Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma

Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma: A Randomized Phase 2 Investigator-Initiated Trial

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

136

Planned (sponsor's estimate)

Start

Jul 15, 2026

Primary completion

Nov 30, 2028

Study completion Jun 30, 2029

Sponsor

Lead sponsor
National Cancer Center, JapanGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Jul 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the clinical efficacy of perioperative treatment with S-1 + oxaliplatin (SOX)+ HLX10 compared with SOX as the control in patients with cT3-4N1-3M0 PD-L1-positive (CPS ≥ 5) locally advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, in a placebo-controlled, double-blind, randomized phase II investigator-initiated clinical study.

Conditions

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

  • serplulimabDrug

    Patients receive perioperative treatment with S-1 plus oxaliplatin (SOX) in combination with Serplulimab.

  • PlaceboDrug

    Patients receive perioperative treatment with S-1 plus oxaliplatin (SOX) in combination with placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological complete response (pCR) rate by central pathology reviewTime frame: Approximately 4-5 months after randomization (after surgery)

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • Chiba Cancer Center

    Chiba, Chiba, Japan · Recruiting

  • Kyushu Cancer Center

    Fukuoka, Fukuoka, Japan · Recruiting

  • Gifu University Hospital

    Gifu, Gifu, Japan · Recruiting

  • Gunma University Hospital

    Maebashi, Gunma, Japan · Recruiting

  • Hiroshima University Hospital

    Hiroshima, Hiroshima, Japan · Recruiting

  • St. Marianna University Hospital

    Kawasaki, Kanagawa, Japan · Recruiting

  • Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan · Recruiting

  • Saitama Prefectural Cancer Center

    Ina, Kitaadachi-gun, Japan · Recruiting

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan · Recruiting

  • Osaka Medical and Pharmaceutical University Hospital

    Takatsuki, Osaka, Japan · Recruiting

  • Saitama Medical University International Medical Center

    Hidaka, Saitama, Japan · Recruiting

  • Shizuoka Cancer Center

    Nagaizumi-chō, Sunto-gun, Japan · Recruiting

  • National Cancer Center Hospital

    Chuo Ku, Tokyo, Japan · Recruiting

  • Cancer Institute Hospital of JFCR

    Koto-Ku, Tokyo, Japan · Recruiting

  • Keio University Hospital

    Shinjuku-Ku, Tokyo, Japan · Recruiting

  • Asan Medical Center

    Songpa-dong, South Korea · Not yet recruiting

  • National Cancer Center Korea

    Goyang-si, Gyeonggi-do, South Korea · Not yet recruiting

  • Ajou University Hospital

    Suwon, Gyeonggi-do, South Korea · Not yet recruiting

  • Seoul St. Mary's Hospital

    Seocho, Seoul, South Korea · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.